Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Lilly licenses Merus antibody therapy for up to $1.6 billion

by Megha Satyanarayana
January 23, 2021 | A version of this story appeared in Volume 99, Issue 3

 

Eli Lilly and Company will enter a licensing agreement with Merus to develop the Dutch company’s antibody cancer treatment. The deal is worth up to $1.6 billion. Merus’s cancer platform includes 175 T-cell-modulating antibodies that are bidirectional: one part of the antibody binds to a tumor cell and the other to T cells, stimulating them to help kill the tumor cell. Lilly will give Merus $40 million up front.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.